BACKGROUND: The success of longitudinal trials depends greatly on using effective strategies to retain participants and ensure internal validity, maintain sufficient statistical power, and provide for the generalizability of study results. OBJECTIVE: This paper describes the challenges and specific strategies used to retain participants in a Phase 2B safety and effectiveness study of daily oral and vaginal tenofovir formulations for the prevention of HIV-1 infection in the MTN-003 (VOICE) trial in Kampala, Uganda. METHODS: Once enrolled, participants were seen every 28 days at the research site and their study product was re-filled. Challenges to retention included a mobile population, non-disclosure of study participation to spouse/family, and economic constraints. Strategies used to maintain high participation rates included the use of detailed locator information, a participant tracking database, regular HIV/STI testing, and the formation of close bonds between staff and subjects. RESULTS: We enrolled 322 women out of the 637 screened. The overall retention rate was 95% over a 3 year follow up period. Only 179 (3%) out of the 6124 expected visits were missed throughout study implementation. Reasons for missed visits included: participants thinking that they did not need frequent visits due to their HIV negative status, time constraints due to commercial sex work, and migration for better employment. CONCLUSIONS: With the implementation of multi-faceted comprehensive follow-up and retention strategies, we achieved very high retention rates in the MTN-003 study. This paper provides a blueprint for effective participant retention strategies for other longitudinal HIV prevention studies in resource-limited settings in Sub-Saharan Africa.
RCT Entities:
BACKGROUND: The success of longitudinal trials depends greatly on using effective strategies to retain participants and ensure internal validity, maintain sufficient statistical power, and provide for the generalizability of study results. OBJECTIVE: This paper describes the challenges and specific strategies used to retain participants in a Phase 2B safety and effectiveness study of daily oral and vaginal tenofovir formulations for the prevention of HIV-1 infection in the MTN-003 (VOICE) trial in Kampala, Uganda. METHODS: Once enrolled, participants were seen every 28 days at the research site and their study product was re-filled. Challenges to retention included a mobile population, non-disclosure of study participation to spouse/family, and economic constraints. Strategies used to maintain high participation rates included the use of detailed locator information, a participant tracking database, regular HIV/STI testing, and the formation of close bonds between staff and subjects. RESULTS: We enrolled 322 women out of the 637 screened. The overall retention rate was 95% over a 3 year follow up period. Only 179 (3%) out of the 6124 expected visits were missed throughout study implementation. Reasons for missed visits included: participants thinking that they did not need frequent visits due to their HIV negative status, time constraints due to commercial sex work, and migration for better employment. CONCLUSIONS: With the implementation of multi-faceted comprehensive follow-up and retention strategies, we achieved very high retention rates in the MTN-003 study. This paper provides a blueprint for effective participant retention strategies for other longitudinal HIV prevention studies in resource-limited settings in Sub-Saharan Africa.
Authors: Richard T Lester; Paul Ritvo; Edward J Mills; Antony Kariri; Sarah Karanja; Michael H Chung; William Jack; James Habyarimana; Mohsen Sadatsafavi; Mehdi Najafzadeh; Carlo A Marra; Benson Estambale; Elizabeth Ngugi; T Blake Ball; Lehana Thabane; Lawrence J Gelmon; Joshua Kimani; Marta Ackers; Francis A Plummer Journal: Lancet Date: 2010-11-09 Impact factor: 79.321
Authors: N A Hessol; M Schneider; R M Greenblatt; M Bacon; Y Barranday; S Holman; E Robison; C Williams; M Cohen; K Weber Journal: Am J Epidemiol Date: 2001-09-15 Impact factor: 4.897
Authors: Victoria Villacorta; Susan Kegeles; Jerome Galea; Kelika A Konda; José Pajuelo Cuba; Carlos F Cáceres Palacios; Thomas J Coates Journal: Clin Trials Date: 2007 Impact factor: 2.486
Authors: Danielle F Haley; Jonathan Lucas; Carol E Golin; Jing Wang; James P Hughes; Lynda Emel; Wafaa El-Sadr; Paula M Frew; Jessica Justman; Adaora A Adimora; Christopher Chauncey Watson; Sharon Mannheimer; Anne Rompalo; Lydia Soto-Torres; Zandraetta Tims-Cook; Yvonne Carter; Sally L Hodder Journal: AIDS Patient Care STDS Date: 2014-04 Impact factor: 5.078
Authors: Eugene Ruzagira; Symon Wandiembe; Andrew Abaasa; Agnes N Bwanika; Ubaldo Bahemuka; Pauli Amornkul; Matthew A Price; Heiner Grosskurth; Anatoli Kamali Journal: PLoS One Date: 2011-08-31 Impact factor: 3.240
Authors: Noah Kiwanuka; Ali Ssetaala; Annet Nalutaaya; Juliet Mpendo; Matthias Wambuzi; Annet Nanvubya; Simon Sigirenda; Paul Kato Kitandwe; Leslie Elizabeth Nielsen; Apolo Balyegisawa; Pontiano Kaleebu; Josephine Nalusiba; Nelson Kaulukusi Sewankambo Journal: PLoS One Date: 2014-05-27 Impact factor: 3.240
Authors: Sarah F Rapaport; Austin D Peer; Nikita Viswasam; Elizabeth Hahn; Sofia Ryan; Gnilane Turpin; Carrie E Lyons; Stefan Baral; Bhakti Hansoti Journal: AIDS Behav Date: 2022-08-01
Authors: Zachary Kwena; Sarah Nakamanya; Gertrude Nanyonjo; Elialilia Okello; Pat Fast; Ali Ssetaala; Bertha Oketch; Matt Price; Saidi Kapiga; Elizabeth Bukusi; Janet Seeley Journal: BMC Public Health Date: 2020-06-15 Impact factor: 3.295